Skip to main content
×
Home

Translational research in oncology: key bottlenecks and new paradigms

  • Richard Simon (a1)
Abstract

Translational research is about transforming progress in basic research into products that benefit patients. Here I discuss some of the key obstacles to effective translational research in oncology that have previously received limited attention. Basic research often does not go far enough for straightforward clinical translation, and long-term, high-risk endeavours to fill these key gaps have not been adequately addressed either by industry or by the culture of investigator-initiated research. These key gaps include the identification of causative oncogenic mutations and new approaches to regulating currently undruggable targets such as tumour suppressor genes. Even where an inhibitor of a key target has been identified, new approaches to clinical development are needed. The current approach of treating broad populations of patients based primarily on primary cancer site is not well suited to the development of molecularly targeted drugs. Although developing drugs with predictive diagnostics makes drug development more complex, it can improve the success rate of development, as well as provide benefit to patients and the economics of healthcare. I review here some prospective Phase III designs that have been developed for transition from the era of correlative science to one of reliable predictive and personalised oncology.

Copyright
References
Hide All
1Jemal A., Ward E. and Thun M. (2010) Declining death rates reflect progress against cancer. PLoS ONE 5, e9584
2Sawyers C.L. (2008) Translational research: are we on the right track? Journal of Clinical Investigation 118, 3798-3801
3Nathan D.G. and Varmus H.E. (2000) The National Institutes of Health and clinical research: a progress report. Nature Medicine 6, 1201-1204
4Sung N.S. et al. (2003) Central challenges facing the national clinical research enterprise. Journal of the American Medical Association 289, 1278-1287
5Hawk E.T. et al. (2008) The translational research working group developmental pathways: introduction and overview. Clinical Cancer Research 14, 5664-5671
6Marincola F.M. (2003) Translational medicine: a two-way road. Journal of Translational Medicine 1, 1-2
7Zerhouni E.A. (2005) US biomedical research: basic, translational, and clinical sciences. Journal of the American Medical Association 294, 1352-1358
8Druker B.J. (2009) Perspectives on the development of imatinib and the future of cancer research. Nature Medicine 15, 1149-1152
9Lydon N. (2009) Attacking cancer at its foundation. Nature Medicine 15, 1153-1157
10Stratton M.R., Campbell P.J. and Futreal A.A. (2009) The cancer genome. Nature 458, 719-724
11Workman P. (2003) The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemotherapy Pharmacology 52, S45-S56
12Weinstein I.B. and Joe A.K. (2006) Mechanisms of disease: oncogene addiction – a rationale for molecular targeting in cancer therapy. Nature Clinical Practice: Oncology 3, 448-457
13Sawyers C.I. (2009) Shifting paradigms: the seeds of oncogenic addiction. Nature Medicine 15, 1158-1161
14Knudson A. (1971) Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Science 68, 820-823
15Moolgavkar S.H. (1986) Carcinogenesis modeling: from molecular biology to epidemiology. Annual Review of Public Health 7, 151-169
16Zhang X. and Simon R. (2005) Estimating the number of rate-limiting genomic changes for human breast cancer. Breast Cancer Research and Treatment 91, 121-124
17Simon R. and Zhang X. (2008) On the dynamics of breast tumor development in women carrying germline BRCA1 or BRCA2 mutations. International Journal of Cancer 122, 1916-1917
18Armitage P. and Doll R. (1957) A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. British Journal of Cancer 11, 161-169
19Loeb L.A. (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Research 51, 3075-3079
20Tomlinson I. and Bodmer W. (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nature Medicine 5, 11-12
21Hanahan D. and Weinberg R.A. (2000) The hallmarks of cancer. Cell 100, 57-70
22Beerenwinkel N. et al. (2007) Genetic progression and the waiting time to cancer. PLoS Computational Biology 3, 2239-2246
23Elenbaas B. et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes and Development 15, 50-65
24Sawyers C.L. (2008) The cancer biomarker problem. Nature 452, 548-552
25Pusztai L. (2004) Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics 5, 451-454
26Pusztai L., Anderson K. and Hess K.R. (2007) Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clinical Cancer Research 13, 6080-6086
27Hess K.R. et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology 24, 4236-4244
28Simon R. and Maitournam A. (2005) Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 10, 6759-6763
29Simon R. and Maitournam A. (2006) Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and correction. Clinical Cancer Research 12, 3229
30Maitournam A. and Simon R. (2005) On the efficiency of targeted clinical trials. Statistics in Medicine 24, 329-339
31Hoering A., LeBlanc M. and Crowley J. (2008) Randomized phase III clinical trial designs for targeted agents. Clinical Cancer Research 14, 4358-4367
32Mandrekar S. et al. (2005) Clinical trial designs for prospective validation of biomarkers. American Journal of Pharmacogenomics 5, 317-325
33Mandrekar S. and Sargent D. (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology 27, 4027-4034
34Simon R. (2008) Using genomics in clinical trial design. Clinical Cancer Research 14, 5984-5993
35Simon R. (2008) Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Review of Molecular Diagnostics 2, 721-729
36Sargent D.J. et al. (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 23, 2020-2027
37Mandrekar S. and Sargent D. (2009) Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of Biopharmaceutical Statistics 19, 530-542
38Freidlin B., McShane L.M. and Korn E.L. (2010) Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 102, 152-160
39Pusztai L. and Hess K.R. (2004) Clinical trial design for microarray predictive marker discovery and assessment. Annals of Oncology 15, 1731-1737
40Zhou X. et al. (2008) Bayesian adaptive design for targeted therapy development in lung cancer – a step toward personalized medicine. Clinical Trials 5, 181-193
41McShane L.M., Hunsberger S. and Adjei A.A. (2009) Effective incorporation of biomarkers into phase II trials. Clinical Cancer Research 15, 1898-1905
42Jiang W., Freidlin B. and Simon R. (2007) Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 99, 1036-1043
43Freidlin B. and Simon R. (2005) Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11, 7872-7878
44Freidlin B., Jiang W. and Simon R. (2010) The cross-validated adaptive signature design for predictive analysis of clinical trials. Clinical Cancer Research 16, 691-698
45Simon R. (2010) Clinical trials for predictive medicine: new challenges and paradigms. Clinical Trials Mar 25; [Epub ahead of print]
46Simon R.M., Paik S. and Hayes D.F. (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 101, 1-7
47Jones S. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806
Sawyers C.L. (2008) The cancer biomarker problem. Nature 452, 548-552
Stratton M.R., Campbell P.J. and Futreal A.A. (2009) The cancer genome. Nature 458, 719-724
Freidlin B., Jiang W. and Simon R. (2010) The cross-validated adaptive signature design for predictive analysis of clinical trials. Clinical Cancer Research 16, 691-698
Freidlin B., McShane L.M. and Korn E.L. (2010) Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 102, 152-160
Simon R. (2008) Using genomics in clinical trial design. Clinical Cancer Research 14, 5984-5993

The website of the Biometric Research Branch of the National Cancer Institute contains extensive material and web-based computer programs for the planning of genomic clinical trials and the analysis of genomic data:

http://brb.nci.nih.gov

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 3
Total number of PDF views: 10 *
Loading metrics...

Abstract views

Total abstract views: 111 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st November 2017. This data will be updated every 24 hours.